Literature DB >> 32002586

Igalan from Inula helenium (L.) suppresses the atopic dermatitis-like response in stimulated HaCaT keratinocytes via JAK/STAT3 signaling.

Thien T P Dao1, Kwangho Song1, Jee Young Kim1, Yeong Shik Kim2,3.   

Abstract

OBJECTIVE: This study aimed to evaluate the protective effect of igalan, a sesquiterpene lactone isolated from Inula helenium (L.), on inhibiting inflammation, regulating the epidermal differentiation gene expression, and reactive oxygen species scavenging in atopic dermatitis (AD)-like inflammatory keratinocytes.
METHODS: HaCaT human keratinocytes were treated with igalan at indicated concentrations before being activated by a combination of TNF-α and IFN-γ or IL-4 representative for T-helper 1 and T-helper 2 cell cytokines, which are associated with AD pathogenesis.
RESULTS: By inhibiting the NF-κB pathway as well as the STAT activation, igalan could downregulate several marker inflammatory genes in AD, such as TARC/CCL17, MDC/CCL22, and RANTES/CCL5. In contrast, igalan, acting as JAK inhibitor, could promote the mRNA expression levels of the genes FLG, LOR, KRT10, and DSC1, which encode for essential proteins responsible for keratinocyte differentiation, by inhibiting STAT3 signaling. Furthermore, igalan exerts its antioxidant effect through activating the Nrf2 pathway, triggering the expression of some enzymes that contribute to preventing intracellular ROS generation during inflammation.
CONCLUSION: These findings indicate that igalan, via suppressing JAK/STAT3 signaling, could impair the production of pro-inflammatory chemokines and enhance expression levels of several genes involved in keratinocyte differentiation in AD-like stimulated keratinocytes.

Entities:  

Keywords:  Antioxidant; Atopic dermatitis; JAK/STAT3 signaling; Nf-κb pathway; Nrf2 activation; Sesquiterpene lactones

Mesh:

Substances:

Year:  2020        PMID: 32002586     DOI: 10.1007/s00011-020-01322-4

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  33 in total

1.  Increased oxidative stress in childhood atopic dermatitis.

Authors:  N Omata; H Tsukahara; S Ito; Y Ohshima; M Yasutomi; A Yamada; M Jiang; M Hiraoka; M Nambu; Y Deguchi; M Mayumi
Journal:  Life Sci       Date:  2001-06-01       Impact factor: 5.037

2.  Overexpression of the suppressor of cytokine signalling 3 (SOCS3) in severe atopic dermatitis.

Authors:  Y Horiuchi; S-J Bae; I Katayama
Journal:  Clin Exp Dermatol       Date:  2006-01       Impact factor: 3.470

3.  Guidelines for the management of atopic dermatitis (eczema) for pharmacists.

Authors:  Ian T Y Wong; Ross T Tsuyuki; Amanda Cresswell-Melville; Philip Doiron; Aaron M Drucker
Journal:  Can Pharm J (Ott)       Date:  2017-05-30

4.  A cell-based assay system for monitoring NF-kappaB activity in human HaCat transfectant cells.

Authors:  K Y Moon; B S Hahn; J Lee; Y S Kim
Journal:  Anal Biochem       Date:  2001-05-01       Impact factor: 3.365

Review 5.  Adverse effects of topical glucocorticosteroids.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Robert A Schwartz; Michael J Cork
Journal:  J Am Acad Dermatol       Date:  2006-01       Impact factor: 11.527

Review 6.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.

Authors:  John J O'Shea; Robert Plenge
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

7.  Chemokine RANTES in atopic dermatitis.

Authors:  J Glück; B Rogala
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1999       Impact factor: 4.291

8.  Characterization of socioeconomic status of Japanese patients with atopic dermatitis showing poor medical adherence and reasons for drug discontinuation.

Authors:  Hiroyuki Murota; Satoshi Takeuchi; Makoto Sugaya; Miki Tanioka; Daisuke Onozuka; Akihito Hagihara; Hidehisa Saeki; Shinichi Imafuku; Masatoshi Abe; Yoichi Shintani; Sakae Kaneko; Koji Masuda; Takaaki Hiragun; Naoko Inomata; Yuki Kitami; Yuichiro Tsunemi; Shinya Abe; Miwa Kobayashi; Donald E Morisky; Masutaka Furue; Norihito Katoh
Journal:  J Dermatol Sci       Date:  2015-06-16       Impact factor: 4.563

9.  TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice.

Authors:  Juan Manuel Leyva-Castillo; Pierre Hener; Hua Jiang; Mei Li
Journal:  J Invest Dermatol       Date:  2012-07-26       Impact factor: 8.551

Review 10.  Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity.

Authors:  Teruki Dainichi; Sho Hanakawa; Kenji Kabashima
Journal:  J Dermatol Sci       Date:  2014-09-06       Impact factor: 4.563

View more
  4 in total

1.  From Monographs to Chromatograms: The Antimicrobial Potential of Inula helenium L. (Elecampane) Naturalised in Ireland.

Authors:  Ciara-Ruth Kenny; Anna Stojakowska; Ambrose Furey; Brigid Lucey
Journal:  Molecules       Date:  2022-02-18       Impact factor: 4.411

Review 2.  The Role of KEAP1-NRF2 System in Atopic Dermatitis and Psoriasis.

Authors:  Tatsuya Ogawa; Yosuke Ishitsuka
Journal:  Antioxidants (Basel)       Date:  2022-07-19

3.  Unveiling the Ability of Witch Hazel (Hamamelis virginiana L.) Bark Extract to Impair Keratinocyte Inflammatory Cascade Typical of Atopic Eczema.

Authors:  Stefano Piazza; Giulia Martinelli; Andrea Magnavacca; Marco Fumagalli; Carola Pozzoli; Massimo Terno; Luisa Canilli; Marco Angarano; Nicole Maranta; Mario Dell'Agli; Enrico Sangiovanni
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

Review 4.  Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

Authors:  Masutaka Furue
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.